Fintel reports that on January 8, 2025, UBS upgraded their outlook for Novo Nordisk A (NYSE:NVO) from Sell to Buy.
Analyst Price Forecast Suggests 61.15% Upside
As of December 23, 2024, the average one-year price target for Novo Nordisk A is $137.98/share. The forecasts range from a low of $81.60 to a high of $174.20. The average price target represents an increase of 61.15% from its latest reported closing price of $85.62 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Novo Nordisk A is 241,210MM, a decrease of 10.86%. The projected annual non-GAAP EPS is 41.89.
What is the Fund Sentiment?
There are 2,103 funds or institutions reporting positions in Novo Nordisk A. This is an decrease of 61 owner(s) or 2.82% in the last quarter. Average portfolio weight of all funds dedicated to NVO is -9.28%, an increase of 1,510.17%. Total shares owned by institutions increased in the last three months by 0.04% to 381,997K shares. 
The put/call ratio of NVO is 0.82, indicating a bullish outlook.
What are Other Shareholders Doing?
Jennison Associates holds 20,196K shares. In its prior filing, the firm reported owning 21,221K shares , representing a decrease of 5.07%. The firm decreased its portfolio allocation in NVO by 58.83% over the last quarter.
Bank Of America holds 14,326K shares. In its prior filing, the firm reported owning 14,189K shares , representing an increase of 0.96%. The firm decreased its portfolio allocation in NVO by 80.12% over the last quarter.
Fisher Asset Management holds 13,305K shares. In its prior filing, the firm reported owning 13,371K shares , representing a decrease of 0.49%. The firm decreased its portfolio allocation in NVO by 21.81% over the last quarter.
Fayez Sarofim holds 12,217K shares. In its prior filing, the firm reported owning 12,552K shares , representing a decrease of 2.74%. The firm decreased its portfolio allocation in NVO by 75.43% over the last quarter.
Price T Rowe Associates holds 9,583K shares. In its prior filing, the firm reported owning 9,504K shares , representing an increase of 0.83%. The firm decreased its portfolio allocation in NVO by 19.07% over the last quarter.
Novo Nordisk Background Information
(This description is provided by the company.)
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in nine countries, and affiliates or offices in five countries.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
